Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
A deep philosophical and financial divide exists within the U.S. biopharma industry regarding China. Some leaders, like Ginkgo Bioworks' CEO, advocate for protectionist investment controls to counter Chinese competition. In contrast, others, like RA Capital's Peter Kolchinsky, argue such walls harm global innovation, revealing a core debate often aligned with financial interests.
Related Insights
The argument against adopting lower foreign drug prices is framed as a national security imperative. Proponents argue that such price controls would slash U.S. R&D investment, allowing China to dominate the bio-pharma sector and potentially weaponize future drug supply chains in a crisis.
Large multinational pharma companies publicly express concern about the threat from China's biopharma sector. Simultaneously, these same companies are investing billions, actively integrating China into the global ecosystem and contradicting their own zero-sum game narrative.
US policymakers debating restrictions on China's biotech sector may be influenced by competition in industries like semiconductors and electric vehicles. This approach is flawed because it fails to recognize that the life sciences industry is fundamentally different, with unique dynamics in innovation, IP, and global collaboration that don't map directly from other technology sectors.
A disconnect exists between the public rhetoric of U.S. pharma leaders, who frame China's growing biotech sector as a threat, and their corporate actions. These same companies are investing heavily in Chinese R&D and manufacturing, revealing a dual strategy of public caution and private commitment to integrating China into the global biopharma ecosystem.
The US biotech industry is divided on collaborating with Chinese firms. A significant group feels trapped in a prisoner's dilemma: they would prefer if everyone stopped working with Chinese companies, but feel forced to engage because if their competitors do, they'll be at a significant disadvantage by opting out.
In stark contrast to the often adversarial U.S. perspective, the European biopharma community increasingly views China as a strategic partner. The focus is not on competition but on integration, leveraging China as a "force multiplier" for global drug development and commercialization, highlighting a significant divergence in geopolitical business strategy.
The US biotech industry's fixation on the "China threat" is largely a reaction to losing its undisputed global leadership position. Having never faced such potent competition, the industry is unsettled. The fact that the competitor is China, a geopolitical rival, amplifies this underlying anxiety about being dethroned.
Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.
John Crowley, CEO of Bio, argues the best strategy for US biotech dominance is not protectionism. Instead, the focus should be on improving the US's own competitive advantages, like streamlining regulations and lowering innovation costs, to maintain its lead rather than trying to stifle Chinese research.
The narrative of China as an innovation 'threat' in biopharma may be a deliberate strategy to spur action in the U.S. By creating a sense of urgency and competition, reminiscent of the U.S.-Soviet superpower struggle, the industry may be attempting to mobilize investment and political will, even if the framing is seen as unfortunate.
